BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25030395)

  • 1. The use of gallium-68 labeled somatostatin receptors in PET/CT imaging.
    Ambrosini V; Nanni C; Fanti S
    PET Clin; 2014 Jul; 9(3):323-9. PubMed ID: 25030395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
    Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 68Ga-DOTA-peptides in the diagnosis of NET.
    Ambrosini V; Fanti S
    PET Clin; 2014 Jan; 9(1):37-42. PubMed ID: 25029932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).
    Ambrosini V; Morigi JJ; Nanni C; Castellucci P; Fanti S
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):58-69. PubMed ID: 25677589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
    Gabriel M; Decristoforo C; Kendler D; Dobrozemsky G; Heute D; Uprimny C; Kovacs P; Von Guggenberg E; Bale R; Virgolini IJ
    J Nucl Med; 2007 Apr; 48(4):508-18. PubMed ID: 17401086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
    Ugur O; Kothari PJ; Finn RD; Zanzonico P; Ruan S; Guenther I; Maecke HR; Larson SM
    Nucl Med Biol; 2002 Feb; 29(2):147-57. PubMed ID: 11823119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
    Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement.
    Sako T; Hasegawa K; Nishimura M; Kanayama Y; Wada Y; Hayashinaka E; Cui Y; Kataoka Y; Senda M; Watanabe Y
    Biochem Biophys Res Commun; 2013 Dec; 442(1-2):79-84. PubMed ID: 24220338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution and first clinical results of
    Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.
    Henze M; Schuhmacher J; Hipp P; Kowalski J; Becker DW; Doll J; Mäcke HR; Hofmann M; Debus J; Haberkorn U
    J Nucl Med; 2001 Jul; 42(7):1053-6. PubMed ID: 11438627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT.
    Breer S; Brunkhorst T; Beil FT; Peldschus K; Heiland M; Klutmann S; Barvencik F; Zustin J; Gratz KF; Amling M
    Bone; 2014 Jul; 64():222-7. PubMed ID: 24769333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine tumor imaging with 68Ga-DOTA-NOC: physiologic and benign variants.
    Kagna O; Pirmisashvili N; Tshori S; Freedman N; Israel O; Krausz Y
    AJR Am J Roentgenol; 2014 Dec; 203(6):1317-23. PubMed ID: 25415711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.
    Ambrosini V; Castellucci P; Rubello D; Nanni C; Musto A; Allegri V; Montini GC; Mattioli S; Grassetto G; Al-Nahhas A; Franchi R; Fanti S
    Nucl Med Commun; 2009 Apr; 30(4):281-6. PubMed ID: 19247211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.
    Traub-Weidinger T; Putzer D; von Guggenberg E; Dobrozemsky G; Nilica B; Kendler D; Bale R; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor-based PET/CT of intracranial tumors: a potential area of application for 68 Ga-DOTA peptides?
    Sharma P; Mukherjee A; Bal C; Malhotra A; Kumar R
    AJR Am J Roentgenol; 2013 Dec; 201(6):1340-7. PubMed ID: 24896203
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.